Literature DB >> 7325888

The effect of iron and protein deficiency on plasma levels and parasite uptake of [14C] fenbendazole in rats infected with Nippostrongylus brasiliensis.

R K Prichard, J D Kelly, T D Bolin, V M Duncombe, M R Fagan.   

Abstract

The Nippostrongylus brasiliensis-rat model was used to determine whether iron and protein deficiency, which are commonly associated with parasitic infections, affected the pharmacokinetic behaviour of fenbendazole as measured by plasma concentrations and uptake by worms. Plasma 14C concentrations after [14C] fenbendazole administration were higher in iron and protein-deficient rats than in sufficient rats. However, the uptake of 14C by N. brasiliensis in iron and protein-deficient rats was significantly less than in worms from diet-sufficient rats. The reduced anthelmintic uptake by worms in protein and iron-deficient hosts may account, in part, for reduced anthelmintic efficacy under these circumstances. These findings are relevant to understanding variations in response to chemotherapy in populations of parasitised hosts containing malnourished individuals.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7325888     DOI: 10.1038/icb.1981.49

Source DB:  PubMed          Journal:  Aust J Exp Biol Med Sci        ISSN: 0004-945X


  3 in total

1.  Use of fenbendazole-containing therapeutic diets for mice in experimental cancer therapy studies.

Authors:  Qiwen Duan; Yanfeng Liu; Carmen J Booth; Sara Rockwell
Journal:  J Am Assoc Lab Anim Sci       Date:  2012-03       Impact factor: 1.232

2.  Fenbendazole as a potential anticancer drug.

Authors:  Qiwen Duan; Yanfeng Liu; Sara Rockwell
Journal:  Anticancer Res       Date:  2013-02       Impact factor: 2.480

3.  Drug-Induced Liver Injury in a Patient with Nonsmall Cell Lung Cancer after the Self-Administration of Fenbendazole Based on Social Media Information.

Authors:  Teppei Yamaguchi; Junichi Shimizu; Yuko Oya; Yoshitsugu Horio; Toyoaki Hida
Journal:  Case Rep Oncol       Date:  2021-06-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.